Riptide Antimicrobial Research Highlighted on Defense Department Website

July 3, 2018

SAN FRANCISCO, CA. – Riptide’s research supported by the US Department of Defense Medical Research and Development Program (DMRDP) today became the featured program on the Congressionally Directed Medical Research Programs (CDMRP) website. CDMRP cites examples of outstanding research on its website and in the CDMRP Annual Report.

Read more >

Riptide Addresses JPC-2 Military Expert Review Committee

May 30, 2018

BETHESDA, MD. – On May 29, Riptide Principal Scientist Dr. L. Edward Clemens gave an invited presentation to the JPC-2 Military Infections Disease Research Program (MIDRP) Expert Review Committee, a part of the Congressionally Directed Medical Research Programs (CDMRP).

Read more >

Riptide Scientific Officer Addresses International Biotechnology and Research Conference

April 26, 2018

ROME, ITALY – Riptide Executive Vice President Dr. Henry Lopez gave today’s keynote address to the “Biotech 2018” International Biotechnology and Research Conference.

Read more >

RP-185 Featured in 2018 AACR Presentation

April 18, 2018

SAN FRANCISCO, CA. – Riptide Bioscience’s lead drug candidate RP-185 was the subject of an invited poster presentation at this month’s annual meeting of the American Association for Cancer Research (AACR). The AACR meeting is the year’s premier venue for announcing the most significant new research into the etiology and treatment of cancer.

Read more >

Riptide Bioscience Announces Grant to Develop Advanced Acne Therapeutics

November 2, 2017

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., today announced its receipt of a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, an agency of the National Institutes of Health. The grant is entitled, Designed Antimicrobial Peptides for Treatment of Infectious Acne Vulgaris.

Read more >


< Additional articles > Next page